DRIO

+ Watchlist + Portfolio

DarioHealth Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $7.16
52-Week Range: $5.85 – $17.74
Market Cap: $70.26M
P/E (TTM): —
EPS (TTM): -15.02
Dividend Yield: —

Advanced Metrics

Price/Book: 0.96
PEG Ratio: —
Return on Equity: -59.91%
Return on Assets: -19.42%
Gross Margin: 61.57%
Operating Margin: -125.15%
Profit Margin: -169.87%
Current Ratio: 2.31
Debt/Equity: 0.59
Total Debt: $32.41M
Free Cash Flow: $-12.35M
Revenue Growth: -3.60%
Earnings Growth: —
Enterprise Value: $89.30M

DRIO Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$27.66M	$20.35M	$27.04M	$22.36M
Cost of Revenue	$18.00M	$14.37M	$13.77M	$9.69M
Gross Profit	$9.65M	$5.98M	$13.27M	$12.66M
Research & Development	$19.65M	$20.25M	$24.18M	$13.79M
Selling, General & Admin	$46.82M	$41.92M	$46.83M	$35.53M
Operating Expenses	$66.47M	$62.17M	$71.01M	$49.32M
Operating Income	-$56.81M	-$56.19M	-$57.74M	-$36.66M
EBITDA	-$55.60M	-$51.20M	-$37.17M	-$35.45M
Pretax Income	-$62.19M	-$59.36M	-$44.60M	-$41.61M
Income Tax	$4.00K	$64.00K	-$1.85M	$105.00K
Net Income	-$62.19M	-$59.43M	-$42.75M	-$41.71M
Diluted EPS	-50.80	-38.60	-12.27	-10.12
Diluted Shares	1.18M	1.42M	2.45M	3.98M

DRIO Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$49.36M	$36.80M	$27.76M	$21.80M
Receivables	$7.14M	$3.64M	$5.35M	$2.93M
Inventory	$7.96M	$5.06M	$4.75M	$4.32M
Current Assets	$65.52M	$47.33M	$40.53M	$35.07M
Total Assets	$119.19M	$96.39M	$118.88M	$110.08M
Current Liabilities	$19.35M	$12.49M	$16.64M	$9.32M
Long-Term Debt	$18.11M	$24.59M	$23.47M	$30.75M
Total Debt	$28.05M	$29.54M	$30.19M	$31.75M
Total Liabilities	$39.19M	$38.24M	$46.87M	$42.15M
Retained Earnings	-$285.85M	-$349.36M	-$390.34M	-$452.08M
Shareholders' Equity	$80.00M	$58.14M	$72.02M	$67.92M
Working Capital	$46.17M	$34.84M	$23.89M	$25.74M
Net Debt	—	—	$1.16M	$8.94M

DRIO Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$47.84M	-$30.38M	-$38.56M	-$25.94M
Capital Expenditure	-$573.00K	-$584.00K	-$138.00K	-$142.00K
Free Cash Flow	-$48.42M	-$30.96M	-$38.70M	-$26.08M
Depreciation & Amortisation	$4.72M	$4.99M	$7.43M	$3.14M
Stock-Based Compensation	$16.98M	$19.70M	$15.80M	$9.37M
Investing Cash Flow	-$573.00K	-$547.00K	-$8.93M	-$4.34M
Financing Cash Flow	$61.94M	$18.25M	$38.53M	$24.31M
Share Repurchases	-$134.00K	$0.00	—	—
Net Change in Cash	$13.52M	-$12.67M	-$8.96M	-$5.97M

DRIO Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$6.75M	$5.37M	$5.01M	$5.23M	$5.58M
Cost of Revenue	$2.87M	$2.40M	$1.99M	$2.43M	$2.38M
Gross Profit	$3.88M	$2.96M	$3.02M	$2.80M	$3.20M
Research & Development	$4.11M	$3.72M	$3.33M	$2.63M	$2.38M
Selling, General & Admin	$9.18M	$8.44M	$9.17M	$8.73M	$8.12M
Operating Expenses	$13.29M	$12.16M	$12.50M	$11.37M	$10.51M
Operating Income	-$9.41M	-$9.20M	-$9.48M	-$8.56M	-$7.31M
EBITDA	-$7.95M	-$8.40M	-$8.76M	-$7.32M	-$6.52M
Pretax Income	-$9.21M	-$12.99M	-$10.47M	-$8.95M	-$8.19M
Income Tax	$22.00K	$0.00	$0.00	$83.00K	$57.00K
Net Income	-$9.23M	-$12.99M	-$10.47M	-$9.03M	-$8.25M
Diluted EPS	-2.87	-3.60	-2.96	—	-1.25
Diluted Shares	2.37M	2.48M	3.14M	—	6.58M

DRIO Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$27.85M	$21.95M	$31.91M	$21.80M	$14.98M
Receivables	$5.89M	$5.39M	$5.19M	$2.93M	$4.30M
Inventory	$4.62M	$4.61M	$4.87M	$4.32M	$4.17M
Current Assets	$38.56M	$32.17M	$42.19M	$35.07M	$28.73M
Total Assets	$115.60M	$108.33M	$117.73M	$110.08M	$103.28M
Current Liabilities	$19.16M	$9.75M	$9.28M	$9.32M	$9.36M
Long-Term Debt	$18.90M	$30.50M	$30.62M	$30.75M	$30.93M
Total Debt	$30.34M	$31.62M	$31.64M	$31.75M	$31.82M
Total Liabilities	$41.90M	$44.34M	$42.79M	$42.15M	$40.90M
Retained Earnings	-$404.41M	-$422.97M	-$441.83M	-$452.08M	-$460.33M
Shareholders' Equity	$73.70M	$63.99M	$74.93M	$67.92M	$62.38M
Working Capital	$19.41M	$22.42M	$32.91M	$25.74M	$19.38M
Net Debt	$1.34M	$8.54M	—	$8.94M	$15.95M

DRIO Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$6.67M	-$6.03M	-$7.35M	-$5.89M	-$6.03M
Capital Expenditure	-$31.00K	-$44.00K	-$41.00K	-$26.00K	-$31.00K
Free Cash Flow	-$6.70M	-$6.08M	-$7.39M	-$5.91M	-$6.06M
Depreciation & Amortisation	$1.26M	$802.00K	$546.00K	$534.00K	$524.00K
Stock-Based Compensation	$2.34M	$2.04M	$2.95M	$2.04M	$1.44M
Investing Cash Flow	-$31.00K	-$44.00K	-$41.00K	-$4.23M	-$826.00K
Financing Cash Flow	$6.82M	$124.00K	$17.39M	-$19.00K	$0.00
Net Change in Cash	$111.00K	-$5.95M	$10.00M	-$10.13M	-$6.85M

Market Snapshot

About

DarioHealth Corp. is a digital health company offering a digital therapeutics platform for chronic disease management. The company's solutions focus on conditions including diabetes, hypertension, musculoskeletal disorders, and behavioral health. DarioHealth's platform combines biosensors, mobile applications, data analytics, and coaching to provide personalized health management. The company targets both direct-to-consumer users and business-to-business channels including employers, health plans, and providers. DarioHealth aims to improve health outcomes while reducing healthcare costs through its integrated digital care platform.